



Proven Safety with Pradaxa® 150mg BID¹

Pradaxa® 150mg BID provides Asian patients with superior risk reduction in major bleeding and intracranial bleeding*



MAJOR BLEEDING

43%

RISK REDUCTION*

INTRACRANIAL BLEEDING

60%

RISK REDUCTION*

For the reduction of the risk of stroke & systemic embolism in patients with non-valvular atrial fibrillation (SPAF)¹

* vs warfarin

REFERENCES:

1. Hori M, et al. Stroke 2013;44:1891-1896.



Scan QR Code to access PRADAXA® & PRAXBIND® latest prescribing information

For healthcare professionals only.



Boehringer Ingelheim (Malaysia) Sdn. Bhd.
Registration no. 196601000482 (14/09/14)

Suite 15-5 Level 15, Wisma UOA Damansara E, No 6, Jalan Changkat Servatan,
Damansara Heights, 50490 Kuala Lumpur.
Tel: +603 2092 0066 Fax: +603 2095 2818

Pradaxa®
dabigatran etexilate

Praxbind®
idaruciclimab

Closing the Circle